Cambodia

Population 2016: 16 million

### Tuberculosis profile

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality (excludes HIV+TB)</strong></td>
<td>3.2 (2.1–4.4)</td>
<td>20 (14–28)</td>
</tr>
<tr>
<td><strong>Mortality (HIV+TB only)</strong></td>
<td>0.45 (0.29–0.66)</td>
<td>2.9 (1.8–4.2)</td>
</tr>
<tr>
<td><strong>Incidence (includes HIV+TB)</strong></td>
<td>54 (35–78)</td>
<td>345 (223–493)</td>
</tr>
<tr>
<td><strong>Incidence (HIV+TB only)</strong></td>
<td>1.3 (0.85–1.9)</td>
<td>8.5 (5.4–12)</td>
</tr>
<tr>
<td><strong>Incidence (MDR/RR-TB)</strong></td>
<td>1.2 (0.53–1.9)</td>
<td>7.7 (3.4–12)</td>
</tr>
</tbody>
</table>

### Estimated TB burden* (thousands), 2016

<table>
<thead>
<tr>
<th>Age</th>
<th>New cases</th>
<th>Previous treated cases</th>
<th>Total number***</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 14 years</td>
<td>260–840</td>
<td>550</td>
<td></td>
</tr>
<tr>
<td>0-14 years</td>
<td>0–200</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2016**: 62% (43–95)
- **TB patients facing catastrophic total costs**: 0.07 (0.04–0.11)

### TB/HIV care in new and relapse TB patients, 2016

- **Patients with known HIV-status who are HIV-positive**: 721 (3%)
- **on antiretroviral therapy**: 708 (98%)

### Drug-resistant TB care, 2016

- **Estimated MDR/RR-TB cases among notified pulmonary TB cases**: 1.8% (0.77–2.8) 11% (0–23)
- **% notified tested for rifampicin resistance**: 1% 70% 1,542

### Laboratory-confirmed cases

- **MDR/RR-TB**: 101, XDR-TB: 1

### Treatment success rate and cohort size

- **Success**: 94% 35,167
- **Cohort**: 88% 226

### TB preventive treatment, 2016

- **% of HIV-positive people (newly enrolled in care) on preventive treatment**: 20%
- **% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment**: 36% (33–39)

### TB financing, 2017

- **National TB budget (US$ millions)**: 37

*Ranges represent uncertainty intervals
**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
***Includes cases with unknown previous TB treatment history
****Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Data: www.who.int/tb/data